PHPBiotech.wikiThe PHP Biotech Reference

Frequently asked questions about PHP Biotech

From PHPBiotech.wiki, a sourced reference on PHP Biotech, a preclinical oncology company

By the PHP Biotech Wiki editorial team · Published · Last updated

Short answer: PHP Biotech is a preclinical oncology company developing the investigational nanobody PHP53-nb, with no clinical trials registered and no approved products as of 4 October 2026.[4][5] The questions below link to the full articles.

Disclosure: PHPBiotech.wiki is a reference compiled from public sources. It is not the official website of PHP Biotech International Inc.; it is produced by a marketing agency that works for PHP Biotech. It is not written or reviewed by the U.S. Food and Drug Administration or any other regulator, by the journal that published the company’s research, or by any patent office. Nothing on this site is medical advice. PHP53-nb is an investigational, preclinical product: it is not approved for any use and is not available to patients. Facts are cited to public registries, PubMed, patent records, archived web pages, press releases and the company’s own website. See the editorial policy.

What is PHP Biotech?

A preclinical oncology biotechnology company, legal name PHP Biotech International Inc., developing the nanobody drug candidate PHP53-nb.[1][2]

What is PHP53-nb?

An investigational nanobody that, according to the company, carries the crotoxin B-derived peptide 3-NAntC in its binding region, aimed at cancers such as triple-negative breast cancer.[2][3]

Is PHP53-nb in clinical trials?

No. ClinicalTrials.gov listed no study as of 4 October 2026. The company hopes to start clinical trials in 2027.[4][2]

Is PHP53-nb approved?

No. The company states it has not been approved by the U.S. Food and Drug Administration or any other regulatory authority. Nothing on this site is medical advice.[5]

Can patients get PHP53-nb?

No. It is a preclinical research product and no trial is registered.[4]

Is it made from snake venom?

Its peptide is a synthetic peptide derived from crotoxin B, a rattlesnake venom protein.[3]

Has the research been peer reviewed?

One paper, on the 3-NAntC peptide alone, was published in Molecules in April 2024 by company scientists, with company funding.[3]

Does PHP Biotech have patents?

Two published U.S. patent applications, both pending; the company says it has four applications.[6][7][8]

Who is the CEO?

Robert Gahagen, according to the company website.[9]

Who founded PHP Biotech?

Moacyr Bighetti, according to the company.[9]

Where is PHP Biotech located?

Unconfirmed: its website says Southlake, Texas; a 2024 paper says Keller, Texas; a related-name company is registered in Botucatu, Brazil.[1][3][10]

Is PHP Biotech publicly traded?

No SEC filings were found for it in EDGAR as of 4 October 2026.[11]

How do I contact PHP Biotech?

By email at contact@phpbiotech.com or the contact form on phpbiotech.com.[12]

Where will PHP Biotech present next?

The company says it will take part in the 3rd Annual Oncology Venture, Innovation & Partnering Summit in Cambridge, Massachusetts, on 19–20 October 2026.[13][14]

Is this the official website?

No. The official website is phpbiotech.com. This reference is produced by a marketing agency that works for PHP Biotech.

References

  1. ^ a b Home page. PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  2. ^ a b c “Our Science” (including the science FAQ). PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  3. ^ a b c d Bezerra P, Motti EF. “3-NAntC: A Potent Crotoxin B-Derived Peptide against the Triple-Negative MDA-MB-231 Breast Cancer Cell Line.” Molecules 2024;29(7):1646. doi:10.3390/molecules29071646. PMID 38611925. PubMed, U.S. National Library of Medicine. Retrieved 4 October 2026.
  4. ^ a b c ClinicalTrials.gov search results for “PHP53-nb”, “PHP53”, “Pepcrotament”, “3-NAntC” and sponsor “PHP Biotech” (no studies found). U.S. National Library of Medicine, ClinicalTrials.gov. Retrieved 4 October 2026.
  5. ^ a b “PHP Biotech Identifies uPAR as the Cellular Entry Receptor for Its PHP53-nb Anti-Tumor Nanobody” (Southlake, Texas, 18 September 2026). PressAdvantage newsroom (company press release). Retrieved 4 October 2026.
  6. ^ US 2023/0364204 A1, “Bioactive Peptides, Compositions, Production Process, and Use of Bioactive Peptides as Anti-Tumoral Agents” (application 18/313,141). Google Patents (U.S. Patent and Trademark Office data). Retrieved 4 October 2026.
  7. ^ US 2026/0041783 A1, “Nanobody platform, Peptide-modified Nanobody, Production Process, and Use” (application 19/223,678). Google Patents (U.S. Patent and Trademark Office data). Retrieved 4 October 2026.
  8. ^ “What Is a Nanobody?” (blog post, 17 August 2026). PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  9. ^ a b “Our Team”. PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  10. ^ CNPJ 40.622.810/0001-02: PHP Biotech Pesquisa e Desenvolvimento S.A. (company registration record). Receita Federal do Brasil, via the BrasilAPI CNPJ service. Retrieved 4 October 2026.
  11. ^ EDGAR company and full-text search for “PHP Biotech” (no filings found). U.S. Securities and Exchange Commission. Retrieved 4 October 2026.
  12. ^ “Contact Us”. PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  13. ^ “Oncology Summit” event page. PHP Biotech International Inc. (phpbiotech.com). Retrieved 4 October 2026.
  14. ^ “PHP Biotech to Present Nanobody Panel and Sponsor 3rd Annual Oncology Venture, Innovation & Partnering Summit” (25 September 2026). PressAdvantage newsroom (company press release). Retrieved 4 October 2026.